Additional file 1 of Non-canonical activation of MAPK signaling by the lncRNA ASH1L-AS1-encoded microprotein APPLE through inhibition of PP1/PP2A-mediated ERK1/2 dephosphorylation in hepatocellular carcinoma

Additional file 1: Table S1. Details of primary antibodies for WB, IF and Co-IP. Table S2. Details of primers for qPCR. Table S3. Protein-protein interactome of the microprotein APPLE in HCC. Table S4. Differentially expressed genes between patients with high and low ASH1L-AS1 expression. Table S5. Prediction of 77 potential transcription factors binding to the ASH1L-AS1 promoter region using the PROMO online tool. Table S6. List of treatment combinations with higher and lower IC50 values in HCC patients with high expression of the E2F1-ASH1L-AS1/APPLE-ERK1/2 axis, indicating reduced efficacy (higher IC50) or increased sensitivity (lower IC50)